A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
← catalyst calendarNCT04170283 · readout in 124 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
955actual
Sites
153
Countries
Australia, China, Czechia +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Malignancies
Interventions
- Drug: Zanubrutinib — also filed as BGB-3111
- Drug: Tislelizumab — also filed as BGB-A317
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to 5 years
Publications
- PMID 40924923 — linked by the registry
- PMID 38502198 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Related
ONC's other studiesmost recently updated first
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Phase 1 · Recruiting
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 3 · Recruiting
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma Phase 1/2 · Recruiting
- A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors Phase 1 · Recruiting
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Phase 3 · Recruiting
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed